Insulin Icodec

Awiqli

Insulin icodec is a basal insulin engineered for once-weekly dosing — a major shift from the daily injections that basal insulin has always required. Its design combines a long fatty-diacid side chain with three amino-acid substitutions in the insulin molecule. The fatty-acid tail binds strongly but reversibly to albumin, the abundant carrier protein in blood, creating a large circulating reservoir of inactive, bound insulin that slowly releases free hormone. The amino-acid changes reduce how quickly the insulin is cleared after it engages its receptor. Together these give icodec a half-life of about one week, so one subcutaneous injection maintains steady background insulin for seven days. The appeal is obvious: roughly 52 injections a year instead of 365, which can ease the burden of therapy and may improve adherence, particularly for people with type 2 diabetes starting basal insulin. Clinical development (the ONWARDS program) compared once-weekly icodec with daily basal insulins across type 1 and type 2 diabetes. Icodec is approved in the European Union, the United Kingdom, Canada, Australia and other regions; in the United States its initial application received a complete response letter, with review focused especially on use in type 1 diabetes. A once-weekly insulin also changes the safety conversation. Because a dose stays active for a week, a hypoglycemia episode cannot be undone by skipping the next dose, and a dedicated titration approach and dose-adjustment tools are used. Icodec is a basal insulin only — it is combined with mealtime insulin or other therapies as needed — and it is a prescription medicine used under medical supervision. It is not a wellness or performance product, and its extended action makes careful dosing especially important.